Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11723528 | 0.81 | ALDH1A1 (0.49) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL29884110 | 0.78 | ALDH1A1 (0.69) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL1697544 | 0.78 | ALDH1A1 (0.69) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL27854240 | 0.74 | CES2 (0.53) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL8242356 | 0.74 | CES2 (0.58) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL3007215 | 0.73 | KDM4E (0.63) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL58595 | 0.73 | ALDH1A1 (0.54) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL10961296 | 0.73 | CES2 (0.57) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL19139420 | 0.73 | TERT (0.47) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL3553076 | 0.72 | CES2 (0.56) | KDM4EHPGDSMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-3578981-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210231661-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-3803402-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Tudag Tu Dresden Aktiengesellschaft (DE) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233779-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Technische Universität Dresden (DE) | 2019-12-12 | — | — | WO | disclosed |
| CN-105377288-B | Use of a combination of XBP1, CD138 and CS1 peptides for the preparation of a medicament | 达纳-法伯癌症研究所股份有限公司 | 2019-11-15 | — | — | CN | disclosed |
| CN-105541582-B | The MBH of alpha, beta unsaturated ketone and allyl acetic acid ester reacts | 浙江大学 | 2017-07-18 | — | — | CN | disclosed |
| US-4775752-A | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-10-04 | — | — | US | disclosed |
| US-4734495-A | Process and intermediates for beta-lactam antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-03-29 | — | — | US | disclosed |
| US-4673737-A | ANTIBIOTICS/ | HARVARD UNIVERSITY (US) | 1987-06-16 | — | — | US | disclosed |
| US-4665171-A | CARBACEPHALOSPORINS | HARVARD UNIVERSITY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0211540-A1 | Intermediates and process for antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-02-25 | — | — | EP | disclosed |
| CN-86104783-A | The method for preparing beta-Lactam antibiotics | — | 1987-02-04 | — | — | CN | disclosed |
| CN-86105247-A | Antibiotic intermediate and preparation method | — | 1987-02-04 | — | — | CN | disclosed |
| EP-0209352-A2 | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | KDM4E 619/4885HPGD 2052/4885SMN1; SMN2 3340/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | KDM4E 619/4885HPGD 2052/4885SMN1; SMN2 3340/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | KDM4E 2931/4885HPGD 2813/4885SMN1; SMN2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.